Tharimmune, Inc. (THAR)
NASDAQ: THAR · Real-Time Price · USD
3.010
+0.220 (7.89%)
At close: Jan 22, 2026, 4:00 PM EST
3.050
+0.040 (1.33%)
Pre-market: Jan 23, 2026, 7:45 AM EST
Tharimmune Market Cap
Tharimmune has a market cap or net worth of $118.98 million as of January 23, 2026. Its market cap has increased by 2,830.03% in one year.
Market Cap
118.98M
Enterprise Value
111.57M
1-Year Change
2,830.03%
Ranking
Category
Stock Price
$3.01
Market Cap Chart
Since the IPO on January 12, 2022, Tharimmune's market cap has increased from $41.18M to $118.98M, an increase of 188.93%. That is a compound annual growth rate of 30.12%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 22, 2026 | 118.98M | 7.75% |
| Dec 31, 2025 | 110.43M | 2,713.07% |
| Dec 31, 2024 | 3.93M | 205.38% |
| Dec 29, 2023 | 1.29M | -71.40% |
| Dec 30, 2022 | 4.49M | -89.09% |
| Jan 12, 2022 | 41.18M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| MacroGenics | 114.18M |
| Acumen Pharmaceuticals | 114.00M |
| Artiva Biotherapeutics | 112.91M |
| Repare Therapeutics | 111.44M |
| Karyopharm Therapeutics | 110.41M |
| Fortress Biotech | 107.70M |
| Oncolytics Biotech | 106.84M |
| Pyxis Oncology | 105.85M |